Cancer drug developer Oncologie raised $80m from investors including Nan Fung Life Sciences and the Nan Fung-funded Pivotal BioVentures China.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Boehringer Ingelheim Venture Fund co-led the oncology drug developer's series A round with Delos Capital and Xeraya Capital.
Zuellig Pharma has paid an undisclosed amount for portfolio company Klinify after investing in the healthcare data software provider two years ago.
The WuXi Biologics, Eli Lilly and Alexandria Real Estate Equities-backed cancer therapy developer is targeting $74.7m in its IPO.
Having confidentially filed in late April, Karuna Therapeutics has publicly applied for an initial public offering that would raise $75m and provide exits to Nan Fung and PureTech Health.
The health testing kit developer has received $14.5m in series C round funding from investors including corporate backer Xiamen C&D.
The medicine discovery technology developer landed $15.9m in a round led by UCHealth that included Presbyterian Healthcare Services, Children’s Hospital Colorado and UnityPoint Health.
The immunotherapy technology developer has set a $230m target for an initial public offering that would offer exits to LabCorp, Illumina, Celgene and BD Biosciences.
Novo, GlaxoSmithKline, Pfizer, AbbVie, ShangPharma and Schrödinger are all in line for exits following the small-molecule drug developer's decision to file for an $86.3m initial public offering.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
